What is HC Wainwright’s Forecast for enGene FY2027 Earnings?

enGene Holdings Inc. (NASDAQ:ENGN) – Equities researchers at HC Wainwright cut their FY2027 EPS estimates for shares of enGene in a report released on Friday, May 8th. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings per share of ($2.14) for the year, down from their previous estimate of ($2.00). HC Wainwright has a “Buy” rating and a $6.00 price target on the stock. The consensus estimate for enGene’s current full-year earnings is ($2.07) per share. HC Wainwright also issued estimates for enGene’s FY2028 earnings at ($1.89) EPS, FY2029 earnings at ($0.78) EPS and FY2030 earnings at ($0.17) EPS.

enGene (NASDAQ:ENGN) last released its quarterly earnings results on Monday, March 9th. The company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($0.55) by $0.11.

Several other analysts have also recently issued reports on the stock. Leerink Partners cut shares of enGene from an “outperform” rating to a “market perform” rating and set a $2.00 price target on the stock. in a research report on Friday. Wells Fargo & Company reiterated an “equal weight” rating and set a $2.00 target price (down from $25.00) on shares of enGene in a report on Friday. Piper Sandler cut shares of enGene from an “overweight” rating to a “neutral” rating and decreased their price target for the company from $7.00 to $4.00 in a research report on Friday. Raymond James Financial lowered enGene from a “strong-buy” rating to an “outperform” rating and set a $4.00 price objective on the stock. in a research report on Friday. Finally, Wall Street Zen cut enGene from a “hold” rating to a “sell” rating in a research note on Saturday, April 18th. Four analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, enGene presently has an average rating of “Hold” and a consensus price target of $13.41.

enGene Price Performance

ENGN opened at $1.49 on Tuesday. The stock’s 50-day moving average price is $7.26 and its 200 day moving average price is $8.20. enGene has a 12-month low of $1.45 and a 12-month high of $12.25. The firm has a market cap of $99.82 million, a price-to-earnings ratio of -0.66 and a beta of -0.02. The company has a current ratio of 11.75, a quick ratio of 11.75 and a debt-to-equity ratio of 0.09.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Cresset Asset Management LLC acquired a new position in enGene during the 2nd quarter worth approximately $36,000. Paloma Partners Management Co purchased a new stake in shares of enGene during the 2nd quarter worth $38,000. Raymond James Financial Inc. grew its stake in shares of enGene by 383.6% during the third quarter. Raymond James Financial Inc. now owns 10,000 shares of the company’s stock worth $68,000 after purchasing an additional 7,932 shares in the last quarter. Hudson Bay Capital Management LP acquired a new position in shares of enGene during the third quarter worth $76,000. Finally, PFS Partners LLC increased its holdings in enGene by 22.2% in the fourth quarter. PFS Partners LLC now owns 11,000 shares of the company’s stock valued at $99,000 after buying an additional 2,000 shares during the last quarter. Hedge funds and other institutional investors own 64.16% of the company’s stock.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.